DNAs(Genentech) Avastin was approved about a year ago for use on colon cancer . The $11B jump was just for the new approval for Avastin on NSCLC . Indications are that Coramsine will raise the bar considerably higher again . It is my guess that Solbec will probably concentrate on orphan drug uses , such as melonoma and mesothelioma with the prospect of accellerated approval before trials are completed .
- Forums
- ASX - By Stock
- SBP
- genentech up $11 billion
SBP
solbec pharmaceuticals limited
genentech up $11 billion, page-4
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Currently unlisted public company.
The Watchlist
VMM
VIRIDIS MINING AND MINERALS LIMITED
Rafael Moreno, CEO
Rafael Moreno
CEO
SPONSORED BY The Market Online